99%+Purity Avanafil Powder (Stendra)
Avanafil is used to treat men who have erectile dysfunction (also called sexual impotence). Avanafil belongs to a group of medicines called phosphodiesterase 5 (PDE5) inhibitors. These medicines prevent an enzyme called phosphodiesterase type-5 from working too quickly. The penis is one of the areas where this enzyme works.
Assay: 99% min.
Character: White to Off-White Cyrstalline Solid.
Usage: Used for the treatment of erectile dysfunction. A phosphodiesterase 5 inhibitor.
Categories: Active Pharmaceutical Ingredients; Cnbio; Erectile Dysfunction; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; API’s.
Certificates:SGS,ISO 9001, GMP
Provide Samples: Yes.
Delivery time: Within 12 hours upon receipt of payment
Payment method: T/T,western union, money gram, bitcoins
Price: Factory price(Negotiable)
Packing: Discreet and Disguised packing to pass the customs.
Delivery methods: EMS, DHL, TNT, FedEx, UPS,etc door to door.
Standard: GMP Enterprise standard.
The min. order is 10 grams.
Storage: Shading, Confined Preservation
Usage:Used for the treatment of erectile dysfunction. A phosphodiesterase 5 inhibitor
|Test Items||Specification||Test Results|
|Description||White or almost white crystalline powder||White crystalline powder|
|Loss of drying||≤1.0%||0.5%|
|TLC||Only one spot||Only one spot|
Avanafil is a highly selective PDE5 inhibitor with IC50 of 1 nM.
Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is known by the trademark names Spedra and was developed by Vivus Inc. In July 2013 Vivus announced partnership with Menarini Group, which will commercialise and promote Spedra in over 40 European countries plus Australia and New Zealand. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina.Other similar drugs are tadalafil and vardenafil.
It is a development of the phosphodiesterase type 5 inhibitors, for the treatment of male sexual dysfunction, at present in the America, EU and Japan have completed phase II clinical trials, phase III clinical trials will start. The product is composed of Japanese Tanabe Pharma Company and VIVUS company development. In addition to oral dosage forms, VIVUS company is also developing Avanafil urethral administration, for not responding to oral dosage forms of patients.
Avanafil is a potent, highly selective phosphodiesterase 5 inhibitor, in vitro experiments showed that the selectivity of phosphodiesterase 5 stronger than . The compound dear compliance weak against other phosphodiesterase, and effect of adenosine receptor decreased, suggesting that the cardiovascular effects of avanafil should be weaker than .
Pre clinical study showed that avanafil and organic nitrate drugs taken in combination to reduce its on blood pressure was significantly weaker than and nitrate drugs with clothes. Moreover, avanafil inhibition of phosphodiesterase 6 is very weak, the relevant visual disturbance suppression may the enzyme phosphodiesterase 5 inhibitor induced and other.